Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares dropped 2.7% on Wednesday after UBS Group lowered their price target on the stock from $28.00 to $24.00. UBS Group currently has a neutral rating ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... the company may face hurdles in achieving optimal financial performance. Debt Management: Pfizer's debt-to-equity ratio is ...

The stock has been trading about 63% below its all-time high. Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years. At its beaten-down price ...